IMS 2023 | Unanswered questions regarding the sequencing of BCMA-targeting agents in multiple myeloma
The introduction of BCMA-targeting immunotherapies in multiple myeloma has transformed the therapeutic landscape of this disease, however, several unanswered questions remain regarding the optimal sequencing of these agents. In this video, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the importance of incorporating patient preference when selecting between BCMA-directed CAR-T cells and bispecific antibodies, and explains other factors that may impact treatment decisions, including the introduction of GPRC5D- and FcRH5-targeting agents. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
